KaloBios Pharmaceuticals Inc.
the company formerly majority owned by controversial biotech investor Martin Shkreli, said late Friday it has filed its outstanding 10-Q for the first quarter and the first six months of 2016. The company is “current with its SEC periodic reporting requirements. Achieving this milestone is crucial to the company’s turnaround,” the company said in a statement. The company lost $17,438 in the first quarter, compared with a loss of $15,662 in the year-ago period. KaloBios emerged from bankruptcy on June 30 with a new management team and new pricing strategy. It fired Shkreli from his role of CEO late last year, after he was arrested on charges of securities fraud relating to another company. KaloBios specializes in drugs to treat rare diseases. Shares, which trade over the counter, were flat.
View more information: https://www.marketwatch.com/story/kalebios-says-its-current-on-its-financials-after-10-q-filing-2016-09-23